Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14330951 | 0.94 | ALDH1A1 (0.53) | POLBLMNASMN1; SMN2USP2TSHR | |
| SCHEMBL12327773 | 0.88 | ALDH1A1 (0.63) | LMNAHTTSMN1; SMN2USP2TSHR | |
| SCHEMBL2326155 | 0.87 | POLB (0.59) | POLBMAPK1LMNAHTTSMN1; SMN2 | |
| SCHEMBL256083 | 0.86 | ALDH1A1 (0.63) | LMNAHTTSMN1; SMN2USP2TSHR | |
| SCHEMBL13804969 | 0.83 | POLB (0.59) | POLBMAPK1LMNAHTTSMN1; SMN2 | |
| SCHEMBL13804968 | 0.83 | POLB (0.55) | POLBMAPK1LMNAHTTSMN1; SMN2 | |
| SCHEMBL18617342 | 0.82 | ALDH1A1 (0.64) | POLBLMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL20885093 | 0.82 | PKM (0.55) | LMNASMN1; SMN2PKMKMT2ANPC1 | |
| SCHEMBL20885033 | 0.81 | ALDH1A1 (0.51) | LMNASMN1; SMN2TSHRKDM4EPKM | |
| SCHEMBL12189230 | 0.81 | SMN1; SMN2 (0.78) | POLBLMNAHTTSMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | POLB 1540/4885MAPK1 298/4885LMNA 4817/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | POLB 1540/4885MAPK1 298/4885LMNA 4817/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | POLB 1540/4885MAPK1 298/4885LMNA 4817/4885 |
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | PI4KA, PIK3CA, PI4KB | POLB 1185/4885MAPK1 420/4885LMNA 2983/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | POLB 1540/4885MAPK1 298/4885LMNA 4817/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | POLB 1669/4885MAPK1 2410/4885LMNA 2236/4885 |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | PI4KA, PI4KB, PIK3CA | POLB 1044/4885MAPK1 525/4885LMNA 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.